Kornimate/medical-research-clean huggingface dataset:
a feasibility study of the surpass aneurysm-embolization system in intracranial arteries

Conditions: Aneurysm

Summary: the purpose of this study is to evaluate safety and performance of the surpass aneurysm-embolization system.


Eligibility criteria:
inclusion criteria: * subject understands the nature of the procedure and provides written informed consent. * subject is willing to return to the investigational site for the thirty day and six month follow-up evaluations. * age 18 years to 80 years. * subject with a non-ruptured saccular, or fusiform intracranial aneurysm arising from a parent vessel with a diameter of \> 2mm and \< 6mm. exclusion criteria: * pregnancy * enrollment in another trial * allergy or contraindication to aspirin, clopidogrel, heparin, local or general anesthesia * history of life threatening allergy to contrast dye. * major surgery within previous 30 days or planned in the next 90 days after enrollment date. * severe neurological deficit that renders the patient incapable of living independently * dementia or psychiatric problem that prevents the patient from completing required follow up * co-morbid conditions that may limit survival to less than one year * subject with anatomy not appropriate for endovascular treatment due to severe intracranial vessel tortuosity or stenosis, or intracranial vasospasm not responsive to medical therapy. * subject with an intracranial mass (tumor (except meningioma), abscess, or other infection), or is undergoing radiation therapy for carcinoma or sarcoma of the head or neck region. * subject has a history of bleeding diathesis or coagulopathy, international normalized ratio (inr) greater than 1.5, or will refuse blood transfusions. * subject has a serum creatinine level greater than 2.0 mg/dl (within 7 days of procedure) which the investigator determines restricts the use of contrast agents. * subject has a previously implanted intracranial stent associated with the symptomatic distribution within the past 12 weeks prior to enrollment date * stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to enrollment date * subject has a previously implanted carotid stent associated with the symptomatic distribution within the past 12 weeks prior to enrollment date * subject has uncontrolled atrial fibrillation or known cardiac disorders likely to be associated with cardioembolic symptoms. * subject had a subarachnoid hemorrhage within 12 weeks prior to the enrollment date. * subject with resistance to asa and/or clopidogrel. * subject with two or more aneurysms in associated distribution - unless the device is used to treat both aneurysms. * subject has a non-treated arteriovenous malformation (avm) in the territory of the target aneurysm. * target aneurysm is expected to require more than one device.
does routine submucosal injection improve complete resection of 4-20 mm neoplastic colorectal polyps?

Conditions: Colorectal Cancer

Summary: this is a prospective, multi-endoscopist, single center, clinical study at tertiary referral center that addresses an important current challenge in the prevention of colorectal cancer (crc), namely, how to improve the complete removal of crc precursors. this study will observe the potential benefit of specific polypectomy technique in conjunction with a systematic submucosal injection prior to the polyp resection. this study will evaluate the completeness and incompleteness of the resection of colorectal neoplastic polyps during the procedures.

non-detection and incomplete resection of neoplastic colorectal polyps have been identified as the main risk factors for the development of crc in patients after a colonoscopy. between 7% and 9% of all newly diagnosed crcs are estimated to be such "interval cancers," occurring after a previous colonoscopy and before the next surveillance examination. the vast majority of interval cancers are caused by incomplete detection or resection during colonoscopy examination. the contribution of incomplete resection towards interval cancer has recently been pointed out by a panel of experts as one of the cornerstones of crc prevention that need to be addressed in future research studies. the primary aim of this study is to examine the incomplete adenoma resection rates when performing a cold snare polypectomy in conjunction with a submucosal injection for endoscopic resection of 4-20 mm non-pedunculated colorectal polyps. the subjects are patients, men and women, aged between 45-80 years old that are scheduled for a colonoscopy. the secondary aims are to identify procedure-related complication rates and patient-, polyp-, and endoscopist-related factors associated with incomplete adenoma resection.

Eligibility criteria:
inclusion criteria: * signed consent form; aged 45-80 years old, indication to undergo a colonoscopy exclusion criteria: * known inflammatory bowel disease; active colitis; coagulopathy; familial polyposis syndrome; poor general health, defined as an american society of anesthesiologists (asa) physical status class \>3; emergency colonoscopies, hospitalized patients or patients referred from the emergency room.

Keywords: colorectal cancer incomplete resection rate submucosal injection neoplastic polyps
endoscopic quality improvement system study

Conditions: Adenoma Colon; Gastric Precancerous Condition

Summary: we intend to develop intelligent quality control and management software based on the work of digestive endoscopic artificial intelligence in the department of gastroenterology, wuhan university renmin hospital, to accurately and comprehensively assess the quality of gastrointestinal endoscopy and to provide a practical basis for improving the quality of digestive endoscopy in our endoscopic center.


Eligibility criteria:
inclusion criteria: endoscopist: 1. endoscopist with more than one year experience in gastrointestinal mirror operation; 2. willing to further improve endoscopic quality through endo.adm feedback; 3. ability to read, understand and sign informed consent; the investigator believes that the subject understands the flow of the clinical study and is willing and able to complete all research procedures and follow-up visits in conjunction with the research process. exclusion criteria: endoscopist: 1. have participated in other clinical trials; 2. frequently attending in academic conference which is difficult to ensure the number of endoscopic operations; 3. endoscopist who were either not present for both parts (phase1 and phase2) of the study. patients: colonoscopy: 1. polyposis syndromes 2. lumen obstruction 3. history of colorectal surgery 4. history of colorectal surgery gastroscopy: 1. obstruction 2. history of gastric surgery
bone augmentation techniques in the mandible posterior region

Conditions: Bone Substitutes; Alveolar Bone Grafting

Summary: this study aims to compare the efficacy of two bone augmentation techniques in the posterior mandible. twenty participants will undergo 40 surgical procedures at espíritu santo university (uees) in samborondon, ecuador. each patient will receive two types of bone grafts: one side will use autogenous cortical bone plates with a 50/50 mixture of autogenous bone and biomaterial (as described by dr. fouad khoury), while the other side will use xenogenous cortical bone plates with the same mixture.


Eligibility criteria:
inclusion criteria: * patients with bilateral mandibular posterior edentulous with atrophy in 4, 5 or 6 cawood and howell stages. * patients who have good plaque control of less than 20% * patients between 18-64 years old exclusion criteria: * systemically compromised patients * smoker patients * pregnant women, breastfeeding or use of oral contraceptives * patients who are taking medication that may affect healing and coagulation * patients with periodontal disease * patients who have undergone chemotherapy and radiotherapy

Keywords: alveolar bone atrophy bone substitutes bone resorption
study of the efficacy of ggon: a cognitive training app for orthorexia nervosa.

Conditions: Orthorexia Nervosa

Summary: the aim of the present study is to evaluate the efficacy of ggon to decrease the maladaptive beliefs associated with orthorexia nervosa (on) in non-clinical adult population. specifically, a randomized controlled trial with crossover assignment design and two groups (experimental and control) will be carried out in adults aged 18-65 years to assess the changes pre and post use the app. it's expected that after the use of the ggon app for 15 days are, at the primary level: decrease in the degree of ascription to dysfunctional beliefs associated with on; and at the secondary level: decrease in orthorexia nervosa symptomatology, in eating symptomatology and in obsessive beliefs; increase in self-esteem; and no changes in drepessive symptomatology. these results are also expected to be maintained in subsequent follow-ups, at 15 days and a month after to finish the app in experimental group, and 15 days after to finish the app in control group.

there is a digital platform called ggtude, which is composed of different modules, each of them aimed at working with different mental health problems. the goal is to provide an easy-to-use tool as a cbt complement to work on the self-dialogue that relates to the core beliefs associated with the psychological problem in particular. to achieve this target, a cognitive training exercise is performed: different sentences appear in the form of beliefs, and the person must identify and accept those beliefs that are functional, adaptive and positive, dragging them to the lower part of the screen; and reject those that are dysfunctional, maladaptive and negative dragging them to the upper part of the screen. there are different modules, for example, to work self-esteem, eating disorders, depression, body image or obsessive-compulsive disorder, that have proven their effectiveness. the ggon app has not efficacy studies. so, it is relevant to evaluate its effectiveness with an rct study.

Eligibility criteria:
inclusion criteria: * ages between 18 and 65. * have a dispositive with internet access. exclusion criteria: * none

Keywords: maladaptive beliefs cognitive therapy mobile app e-health
the effect of roux-en-y gastric bypass on bone turnover

Conditions: Gastric Bypass Surgery; Obesity; Bone Loss

Summary: bone mineral density (bmd) is decreased after roux-en-y gastric bypass (rygb) but whether rygb induces changes in bmd beyond adaptation to major weight loss is not known. we aim to investigate bmd changes in weight bearing (hip, lumbal columna) and in non-weight bearing (forearm) regions before and after maximal weight loss at 1 year and after weight stabilisation at 4 years after rygb. moreover, plasma markers of bone turnover will be studied at fasting and during oral glucose tolerance test.


Eligibility criteria:
inclusion criteria: * participation in previos study ((nct 01202526) exclusion criteria: * treatment of osteoporosis
development of attention and its relationship with emotions in children and adolescents

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: our aim was to describe the development and usability of a mobile device-based game therapy software for adhd.

a total of 51 adhd children and 52 healthy children were included in the study. at baseline, subjects underwent tests such as adhd symptom-related scale assessments, computer-assisted information processing tests, and physiological-psychological tests, after which participants completed a 4-week game intervention training at home. after complete completion of the intervention, subjects repeated all tests from the baseline period and answered treatment satisfaction questions.

Eligibility criteria:
inclusion criteria: * adhd-a. age between 6-12 years, any gender. * adhd-b. outpatient patients diagnosed with adhd according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) criteria. * adhd-c. patients and/or their guardians willing to participate in the study and provide informed consent. participants aged 8 and above should also sign a child's informed consent form. * hc. the control group of healthy participants are recruited from a secondary school in nanjing, matching the age and gender of the adhd group. exclusion criteria: * a. neurodevelopmental disorders such as cerebral palsy, epilepsy, adrenoleukodystrophy, and other similar conditions. * b. severe mental disorders including tic disorders, autism spectrum disorders, intellectual disability, schizophrenia, bipolar disorder, depressive disorders, specific learning disorders, and other significant psychiatric conditions. * c. individuals exhibiting adhd-like symptoms due to hearing impairments. * d. requirement of any central nervous system medication (including both traditional and western medicine as well as dietary supplements) such as antipsychotics or antidepressants at any stage of the study. * e. patients who have received systematic treatment with two different categories of adhd medications without improvement. * f. individuals with color blindness or any other condition that would prevent proper use of the software. * g. history of or current gaming addiction.
study to assess safety and tolerability of opn-6602 in subjects with relapsed and/or refractory multiple myeloma

Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma

Summary: phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of opn-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory mm.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of multiple myeloma (mm) * relapsed or refractory to 3 or more different prior lines of therapy for mm that included immunomodulatory agents, proteosome inhibitors, and anti-cd38 antibody and not a candidate for or intolerant to established therapy known to provide clinical benefit * adequate hematologic, renal, liver, cardiac function exclusion criteria: * monoclonal gammopathy of undetermined significance (mgus), smoldering myeloma, waldenström's macroglobulinemia, or igm myeloma * active plasma cell leukemia * polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (poems syndrome) * prior stevens johnson syndrome * localized radiation therapy to disease site(s) within 2 weeks of the first dose * prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within \<90 days of the first dose of study drug * prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of screening; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded. * prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug * concomitant high-dose corticosteroids (except subjects on chronic steroids given for disorders other than myeloma) * known central nervous system involvement by multiple myeloma * active known second malignancy with exception of adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; adequately treated stage 1 cancer from which the subject is currently in remission and has been in remission for ≥2 years; low-risk prostate cancer with a gleason score \<7 and a psa level \<10 ng/ml; any other cancer from which the subject has been disease-free for ≥3 years * ongoing systemic infection requiring parenteral treatment * poorly controlled type 2 diabetes
ept 100: geranium oil for the relief of neuropathic pain

Conditions: Neuropathic Pain

Summary: the purpose of this study is to determine if geranium oil will relieve a variety of neuropathic pain and some pain relief will last more than 48 hours.

ept 100 study is designed to identify the percentage of people who experience neuropathic pain relief from topical geranium oil from reunion island, determine which neuropathic pain conditions respond best and define the time course of the pain relief.

Eligibility criteria:
inclusion criteria: * 18 years of age or oler * neuralgia or neuropathy with daily pain * at least moderate intensity pain * signed informed consent exclusion criteria: * pregnant or nursing * known allergies to geranium oil or geranium oil fractions

Keywords: geranium oil neuropathy
evaluating the effectiveness of treatment for metacognition in moderate and severe traumatic brain injury

Conditions: Brain Injuries, Traumatic

Summary: metacognition, in-the-moment awareness of performance while engaging in cognitive tasks, is negatively affected by traumatic brain injury (tbi). metacognitive deficits can greatly reduce quality of life for individuals with tbi as functioning in this domain has been closely linked with successful independent living and community re-integration. problematically, there are currently no empirically validated treatment options that address metacognitive deficits after tbi. recent research in healthy samples demonstrates that specific listening interventions may alter neural activation in brain works associated with metacognition and can improve metacognitive functioning; however, it remains unknown if these effects generalize to individuals with tbi. thus, the objective of the proposed study is to use a double-blind, placebo controlled randomized clinical trial to determine the efficacy of applying a specific listening intervention to improve metacognition after tbi and to employ functional magnetic resonance imaging (fmri) to document the neural mechanisms by which the intervention operates.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate or severe brain injury * between the ages of 18 and 59. * able to read and speak english fluently. * tbi at least 1 year ago. exclusion criteria: * pregnant. * left-handed. * color-blind. * diagnosed with significant psychiatric illness (e.g., bipolar, schizophrenia). * receiving or have received inpatient and/or rehabilitative treatment for substance use. * diagnosis of a neurological condition other than tbi (e.g., epilepsy, multiple sclerosis, stroke). * any metal in my body that has not been declared mri-safe by my physician. * impaired independent use of either hand. * any of the following in/on my body that may interfere with mri: pacemaker, implanted electrical devices, brain stimulators, particular types of dental implants, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids), permanent eyeliner, implanted delivery pumps, or shrapnel fragments. * history of engaging in welding and/or metal working activities. * formal training or am a current practitioner of yoga, meditation, and/or mindfulness. * currently involved in any other type of thinking skills and/or emotional treatment, such as psychotherapy.
long covid cutaneous signatures: an arpa funded research project

Conditions: Long COVID; Acute COVID-19; Postural Orthostatic Tachycardia Syndrome (POTS); Diabetic Neuropathy

Summary: this is a prospective, longitudinal study involving 300 participants for a single visit to compare long covid neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.

this is a prospective, longitudinal study involving 300 participants for a single visit to compare long covid neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system. the evaluations will include clinical assessments, neurologic exams, patient reported outcome surveys, and skin biopsies from three locations. data will be collected on the amount of p-syn in cutaneous nerve fibers. the cohorts of interest are as follows: 1. 100 participants with long covid defined by nih pasc criteria 2. 100 participants with acute covid who tested positive for covid without persistent symptoms defined who criteria 3. 50 participants with postural orthostatic tachycardia syndrome (pots) 4. 50 participants with diabetic neuropathy there are no plans for additional visits at this time. if interested to learn more about this study, please complete the form here for someone to contact you. "here" would take you to the said form.

Eligibility criteria:
inclusion criteria: 1. long covid defined by nih pasc criteria or 2. acute covid who tested positive for covid without persistent symptoms or 3. postural orthostatic tachycardia syndrome (pots) or 4. diabetic neuropathy exclusion criteria: 1. clinical evidence of severe peripheral vascular disease 2. history of ulceration, poor wound healing or vascular claudication 3. history of allergic reaction to local anesthesia (for biopsy collection) 4. use of oral anticoagulants (aspirin or plavix alone is allowed) 5. history of a bleeding disorder

Keywords: covid diabetic neuropathy postural orthostatic tachycardia syndrome pots
obesity and obstructive sleep apnea (osa) in children

Conditions: Obstructive Sleep Apnea; Obesity

Summary: the goal of this research is to study the prevalence of sleep disordered breathing and associated morbidity in obese children and to examine the role of diet and physical activity in the treatment of sleep-disordered breathing in obese children.

in a prospective cohort study, obese children will be recruited. after informed consent is obtained, all children will complete a standardized sleep questionnaire and a pediatric daily sleepiness scale questionnaire. all participants will undergo a complete physical examination, blood tests for lipid profile, liver enzymes, and glucose and insulin will be obtained, and liver sonography will be performed to assess for the presence of fatty liver. nasopharyngeal radiographs will be used to assess adenoidal size based on the method by cohen and konak. a standard in-laboratory, overnight polysomnography will be performed, within 2 weeks of enrollment to the study, in the sleep laboratory at asaf harofeh medical center. children with severe obstructive sleep apnea, defined as apnea hypopnea index (ahi) \> 15 will undergo adenotonsillectomy. all children will be referred for a dietary and physical education program. the first visit with the dietician will be considered day 1 of the study. children will than be followed monthly by a dietician. after three months of follow-up, subjects will be divided into two groups. group 1 will include all children who had ahi \> 2 on the initial polysomnography (including children who underwent adenotonsillectomy for ahi \> 15), and group 2 will consist of children who had ahi \ 2 on the second psg.

Eligibility criteria:
inclusion criteria: * bmi at or above the 90th percentile exclusion criteria: * children with chronic lung or liver disease, mental retardation, syndromes (i.e. prader willi syndrome), endocrine abnormalities (hypothyroidism cushing), chronic medical treatment with oral steroids, or with anti-psychiatric or anti-convulsive medications
pharmacokinetics of lu af35700 in subjects with renal impairment

Conditions: Renal Failure

Summary: this study will evaluate the pharmacokinetics of lu af35700 after a single dose tablet to subjects with renal impairment (kidney insufficiency) and compare that with healthy subjects

if the initial data shows a substantial effect in subjects with severe renal impairment, the study will be expanded to include subjects with intermediate level (mild and moderate) of renal impairment.

Eligibility criteria:
inclusion criteria: -healthy subjects: the subject has a glomerular filtration rate as based on creatinine clearance (clcr) ≥90 ml/min (estimated by the cockcroft-gault method) -subjects with renal impairment: the subject has any form of renal dysfunction which includes polycystic kidney disease the subject is classified as having renal impairment at screening according to cockroft-gault method for estimating creatinine clearance: severe: clcr ≤ 29 ml/min moderate: 30 ml/min ≤ clcr ≤ 59 ml/min mild: 60 ml/min ≤ clcr ≤ 89 ml/min exclusion criteria: -the subject has previously been dosed with lu af35700